Cannabis reclassification from Schedule I to Schedule III represents the most significant shift in federal marijuana policy in over fifty years. The change began as a proposal and, in April 2026, became partial reality: the Department of Justice moved certain categories of marijuana to Schedule III, eliminating one of the heaviest financial burdens facing those operators, the Section 280E tax restriction, while a broader rescheduling question heads to a federal hearing. For cannabis business owners, accountants, and investors, the central question is straightforward: what does reclassification actually change, who does it cover, and how should you prepare for what comes next?
This article walks through how the rescheduling process unfolded, what Schedule III status means in legal and tax terms, exactly which businesses are affected by the 2026 order, and the concrete steps operators can take now.
How the Rescheduling Process Worked
The path toward cannabis reclassification began in October 2022, when President Biden directed the Department of Health and Human Services (HHS) and the Attorney General to review how marijuana is scheduled under federal law. HHS completed its scientific and medical evaluation and recommended in August 2023 that marijuana be moved from Schedule I to Schedule III.
From there, the proposed rule entered a multi-stage federal review process. After White House regulatory review, the Drug Enforcement Administration (DEA) published a notice of proposed rulemaking in the Federal Register, triggering a mandatory public comment period.
Public Comment Period and the Stalled Hearing
The public comment period opened on May 21, 2024, and closed on July 22, 2024, drawing roughly 43,000 comments from individuals, businesses, advocacy groups, and government agencies. You can review the proposed rule and the docket directly through the Federal Register.
An Administrative Law Judge (ALJ) hearing was scheduled to follow, giving interested parties a formal opportunity to present evidence. That hearing was postponed in early 2025 and then stayed pending an interlocutory appeal, which left the rulemaking in limbo for much of the year. The DEA derives its authority over scheduling from the Controlled Substances Act, which sets the criteria for each schedule and the procedure for moving a substance between them.
The April 2026 Order
In April 2026, the executive branch broke the logjam with a narrower, faster action. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order, effective April 28, 2026, that moved two specific categories of marijuana from Schedule I to Schedule III: marijuana contained in FDA-approved drug products, and marijuana subject to a state-issued medical marijuana license. All other marijuana, including recreational and adult-use product, unlicensed crops and bulk marijuana, remained in Schedule I.
The DEA also set a separate, expedited administrative hearing to begin June 29, 2026, to consider whether marijuana more broadly should be reclassified to Schedule III. That proceeding is ongoing as of this writing, and its outcome will determine whether the rest of the industry, including adult-use operators, eventually receives the same federal treatment.
What Schedule III Classification Actually Means
Moving cannabis to Schedule III is not the same as full legalization. Schedule III controlled substances are drugs the federal government recognizes as having accepted medical uses with a moderate-to-low potential for physical and psychological dependence. Other Schedule III substances include ketamine, anabolic steroids, and certain formulations of codeine.
The 2026 order marks the first time the federal government has formally placed any form of marijuana on a schedule that acknowledges legitimate medical benefit. For the covered categories, the distinction shifts the legal framework from prohibition to one of regulated medical use. State-legal medical cannabis programs gain a layer of federal legitimacy they have never had, even though reclassification alone does not create a federal licensing framework for commercial cannabis sales.
Pharmaceutical companies and universities holding a Schedule III DEA registration also gain the ability to manufacture, distribute, and research the covered substances without the extraordinary hurdles attached to Schedule I material. Over time, that access could accelerate clinical studies on cannabinoid therapies, dosing protocols, and long-term health outcomes.
How 280E Tax Relief Changes the Financial Picture
What Section 280E Costs Cannabis Operators
The most immediate and financially significant impact of cannabis reclassification is the removal of Internal Revenue Code Section 280E for the businesses it covers. Section 280E prohibits any business that traffics in Schedule I or Schedule II controlled substances from deducting ordinary business expenses on its federal tax returns. While marijuana sat entirely in Schedule I, every state-legal cannabis company, even one operating fully within state law, could not deduct expenses such as rent, payroll, marketing, utilities, or administrative costs.
The result is that affected cannabis businesses pay federal income taxes on their gross profit rather than their net income. They may still reduce taxable income by cost of goods sold, but everything below that line is disallowed. In practice, effective tax rates for cannabis companies often run far higher than the rates other industries face, which has forced many operators onto razor-thin margins, pushed them into heavy debt, or driven them out of business entirely.
The IRS has been explicit on this point, publishing guidance for cannabis and marijuana businesses that confirms how 280E applies and how operators are expected to report income. For any operator still treated as trafficking in a Schedule I substance, that guidance continues to govern how returns are filed.
What Changes When 280E No Longer Applies
Because Section 280E applies only to Schedule I and Schedule II substances, businesses operating under a qualifying state medical marijuana license are no longer subject to the 280E deduction disallowance once their product is treated as Schedule III. Those operators can claim the same federal tax deductions as any other lawful business, including selling expenses, general and administrative costs, depreciation, and employee benefits. For many companies, this single change is the difference between sustained losses and profitability.
The cash flow implications are equally significant. Cannabis businesses have long set aside disproportionate amounts of revenue for tax obligations, limiting their ability to reinvest in operations, expand into new markets, or hire additional staff. Removing the 280E burden frees up capital and makes covered cannabis companies more attractive to lenders and investors who have historically viewed the sector’s tax exposure as a dealbreaker.
It is important to be precise about scope. The relief reaches state-licensed medical operators and FDA-approved products, not recreational or adult-use businesses, which remain in Schedule I and subject to 280E unless and until the broader rescheduling is finalized. Treasury and the IRS have signaled that they plan to issue guidance clarifying how 280E applies to businesses with both covered and non-covered activities, and that this guidance is expected to include a transition rule. Operators with mixed medical and adult-use operations should treat that forthcoming guidance as central to their planning.
Modeling this shift is where proactive tax advisory services become valuable. Knowing the size of the swing, and how it applies to each line of business, helps owners decide how aggressively to invest, hire, or restructure.
What Reclassification Does Not Change
Operators should understand the limits of the 2026 action. Moving covered marijuana to Schedule III does not legalize recreational marijuana at the federal level. Businesses operating in states with adult-use programs still face a patchwork of federal and state regulations, and interstate commerce in cannabis remains prohibited without additional federal legislation.
Banking and Regulatory Gaps Remain
Reclassification also does not resolve cannabis banking challenges overnight. While Schedule III status may reduce perceived risk for some financial institutions, cannabis businesses still need explicit federal banking protections, such as those proposed in the SAFE Banking Act, to gain broad access to traditional financial services.
The path for the rest of the industry also remains uncertain. The expedited hearing that began June 29, 2026, will determine whether marijuana more broadly moves to Schedule III, and legal challenges from opponents could affect both the scope and the timing of any further change. Cannabis business owners should plan around the relief that already exists for covered operations while avoiding irreversible financial decisions that depend on a broader outcome that is not yet final.
How Cannabis Businesses Should Prepare Now
Cannabis operators and their advisors can take concrete steps to position themselves for the post-280E landscape. First, companies should work with their CPA or tax advisor to model what their financials look like with and without 280E restrictions, accounting for which of their activities are covered by the 2026 order and which are not. Understanding the potential tax savings informs reinvestment strategies and capital planning.
Second, businesses should review their bookkeeping practices to confirm that all ordinary and necessary business expenses are being properly tracked and categorized. With 280E lifted for covered operations, clean financial records are critical for claiming deductions and, potentially, filing amended returns or protective claims. Disciplined client accounting services help close gaps in expense documentation well before a deadline forces the issue.
Third, cannabis companies should stay engaged with industry trade groups and legal counsel to monitor both the pending Treasury and IRS guidance and the broader rescheduling hearing. The regulatory timeline can shift based on political developments, legal challenges, or changes in DEA leadership priorities. Operators who want sector-specific guidance can review how our team supports the cannabis industry across tax, accounting, and advisory work.
A practical preparation checklist looks like this: separate cost of goods sold from operating expenses in your chart of accounts, retain documentation for every category of spending, run a side-by-side tax projection with and without 280E for each line of business, and identify the prior years that might support amended filings or protective claims if retrospective relief is granted. The April 2026 order encouraged the Secretary of the Treasury to consider retrospective relief for years when state licensees operated under medical marijuana licenses, but that relief is discretionary and not guaranteed, so clean records are what preserve the option. Each of these steps has value regardless of how the broader hearing resolves.
Frequently Asked Questions
What Is Cannabis Reclassification?
Cannabis reclassification is the process of moving marijuana from Schedule I to Schedule III under the federal Controlled Substances Act. The change acknowledges that the covered forms of cannabis have accepted medical uses and a lower potential for abuse than Schedule I and II drugs. It does not legalize recreational marijuana at the federal level.
Has Marijuana Already Been Moved to Schedule III?
Partly. A final order effective April 28, 2026, moved FDA-approved marijuana drug products and marijuana subject to a state-issued medical marijuana license to Schedule III. Recreational and unlicensed marijuana remained in Schedule I, and a separate DEA hearing beginning June 29, 2026, will consider whether marijuana more broadly should be rescheduled.
How Does Reclassification Affect 280E Taxes?
Section 280E prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Because state-licensed medical marijuana now falls under Schedule III, those operators are no longer subject to the 280E disallowance and can deduct expenses like rent, payroll, and marketing, substantially reducing their effective tax rates. Recreational operators that remain in Schedule I are still subject to 280E.
Is Marijuana Rescheduling the Same as Federal Legalization?
No. Rescheduling to Schedule III recognizes medical use but does not create a framework for legal recreational sales at the federal level. State-level legalization and federal scheduling are separate regulatory tracks, and reclassification alone does not resolve issues like interstate commerce or federal banking access.
Can Cannabis Businesses File Amended Tax Returns After Reclassification?
It depends. Going forward, covered medical operators are no longer subject to 280E. For prior years, the April 2026 order encouraged Treasury to consider retrospective relief, but no such relief is guaranteed, and Treasury and the IRS have indicated that further guidance, including a transition rule, is expected. Operators should consult a qualified CPA and consider protective claims to preserve their position once guidance is published.
How Does Schedule III Status Affect Cannabis Research?
Schedule III classification allows pharmaceutical companies and universities with a DEA registration to manufacture, distribute, and research the covered substances without the heightened barriers required for Schedule I material. Over time, that access could lead to more clinical studies on cannabinoid-based treatments, standardized dosing, and long-term safety data.
